NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) --
WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of bluebird bio Inc. (NASDAQ:BLUE) resulting from allegations that bluebird may have issued materially misleading business information to the investing public.
SO WHAT: If you purchased bluebird securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.
WHAT TO DO NEXT: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=23843 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email case@rosenlegal.com for information on the class action.
WHAT IS THIS ABOUT: On March 26, 2024, before the market opened, bluebird filed an 8-K with the SEC in which it announced, ...